Hot Life Science Investor Mandate 4: Pharma Company In-Licensing Drugs and Devices Used In Hospitals

8 Oct

A specialist healthcare company with offices worldwide is looking to in-license and acquire therapeutics and medical devices that are of strategic interest. The firm is capable of making allocations ranging from £10 million to over £100 and more for later stage acquisitions. The firm is primarily interested in companies that are looking to be marketed in the United States although they are open to global opportunities as well.

The firm is interested in Therapeutic assets and Medical Devices. For therapeutics the firm’s current products include antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. The firm is open to therapeutics within these areas as well as other indications pending they are intended to be hospital products. The firm primarily focuses on small molecule therapeutics. For medical devices the firm is looking for companies that have 510 K approval in Oncology, Vascular and Pulmonary fields. The firm’s current device products include Interventional Oncology products used to treat patients with liver tumors and Interventional Vascular products used to treat patients with severe blood clots.

The firm is interested in working with founding management teams prior to investment and is open to in-licensing from public and private clients.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: